japanes
enceph
viru
jev
arthropodborn
flaviviru
major
caus
acut
viral
enceph
human
approv
drug
avail
specif
treatment
jev
infect
avail
vaccin
effect
clinic
jev
isol
studi
describ
highthroughput
screen
fdaapprov
drug
librari
inhibitor
jev
perform
five
hit
drug
inhibit
jev
infect
select
index
identifi
antivir
activ
five
hit
drug
flaviviru
includ
zika
viru
also
valid
three
five
hit
drug
calcium
inhibitor
addit
type
calcium
inhibitor
confirm
calcium
essenti
jev
infect
like
viral
replic
util
adapt
mutant
analysi
uncov
replac
locat
transmembran
domain
nonstructur
protein
rel
conserv
flavivirus
r
k
confer
jev
resist
manidipin
voltageg
ca
channel
vgcc
inhibitor
without
appar
loss
viral
growth
profil
furthermor
manidipin
indic
protect
mice
jevinduc
lethal
decreas
viral
load
brain
abrog
histopatholog
chang
associ
jev
infect
studi
provid
five
antiflaviviru
candid
identifi
cytoplasm
calcium
novel
antivir
target
treatment
jev
infect
find
report
provid
therapeut
possibl
combat
infect
caus
flavivirus
import
approv
therapi
treatment
japanes
enceph
viru
infect
current
avail
repurpos
approv
drug
would
acceler
develop
therapeut
stratagem
studi
screen
librari
fdaapprov
drug
identifi
five
hit
drug
especi
calcium
inhibitor
exert
antiflaviviru
activ
block
viral
replic
vivo
efficaci
toxic
manidipin
investig
mous
model
jev
infect
viral
target
identifi
gener
adapt
mutant
f
lavivirus
taxonom
classifi
genu
flaviviru
famili
flavivirida
virus
compris
differ
pathogen
japanes
enceph
viru
jev
zika
viru
zikv
dengu
viru
denv
west
nile
viru
wnv
yellow
fever
viru
yfv
flavivirus
arthropod
born
caus
public
health
problem
worldwid
develop
usag
vaccin
flavivirus
jev
yfv
tickborn
enceph
viru
tbev
decreas
rate
morbid
mortal
infect
caus
virus
howev
flavivirusinduc
diseas
still
pandem
therapi
beyond
intens
support
care
current
avail
flavivirus
approxim
positivestrand
rna
genom
contain
singl
open
read
frame
orf
flank
untransl
region
utr
termini
orf
encod
three
structur
protein
includ
capsid
c
membran
premembran
prm
membran
envelop
e
seven
nonstructur
protein
seven
nonstructur
protein
particip
viral
replic
virion
assembl
viru
escap
immun
surveil
date
specif
antivir
activ
flavivirus
avail
address
conduct
screen
librari
fdaapprov
drug
sinc
flavivirus
similar
structur
pathogenesi
first
util
jev
prototyp
screen
drug
librari
subsequ
valid
antivir
activ
zikv
wnv
denv
type
hit
drug
identifi
studi
offer
potenti
new
therapi
treatment
flaviviru
infect
diseas
screen
fdaapprov
drug
librari
inhibitor
jev
infect
recombin
viral
particl
rvp
luciferasereport
replicon
envelop
jev
structur
protein
use
select
inhibitor
focu
inhibit
viru
entri
replic
highthroughput
screen
ht
assay
number
genom
rna
copi
rvp
determin
copiesml
use
standard
curv
gener
plasmid
carri
infecti
clone
ht
assay
condit
includ
seed
cell
densiti
rvp
dose
optim
cell
per
plate
l
copiescel
rvp
infect
dose
respect
optim
condit
signaltobas
sb
ratio
coeffici
variat
cv
z
factor
respect
demonstr
assay
robust
suitabl
largescal
screen
compound
schemat
ht
assay
depict
fig
three
round
screen
five
hit
select
index
si
equal
cytotox
concentr
cc
inhibitori
concentr
ic
select
cc
valu
hit
drug
exhibit
fig
similar
previous
publish
divers
cell
system
determin
use
differ
toxic
assay
three
hit
drug
manidipin
cilnidipin
benidipin
hydrochlorid
dihydropyridin
dhp
voltageg
ca
channel
vgcc
antagonist
pimecrolimu
inhibitor
inflammatori
cytokin
secret
nelfinavir
mesyl
proteas
blocker
five
drug
exhibit
dosedepend
inhibit
jev
rvp
infect
fig
valid
antivir
effect
hit
drug
purchas
commerci
sourc
test
reconfirm
screen
hit
drug
show
antivir
cytotox
effect
similar
found
primari
screen
valid
hit
drug
verifi
result
obtain
luciferas
report
assay
also
investig
antivir
effect
five
hit
drug
wildtyp
jev
strain
expect
ht
assay
five
drug
robustli
inhibit
viru
product
reduct
approxim
log
unit
highest
concentr
approxim
decreas
drug
fig
sharp
decreas
jev
rna
level
also
detect
fig
attenu
rna
level
highdos
middledos
lowdos
group
particular
manidipinetr
group
inhibitori
effect
least
compar
control
show
strong
inhibit
viral
replic
consist
inhibit
viru
replic
product
express
viral
structur
protein
prm
hardli
detect
follow
treatment
drug
high
concentr
fig
overal
result
fig
confirm
five
hit
drug
inhibit
jev
infect
dosedepend
manner
vitro
drug
inhibit
jev
infect
viral
rna
synthesi
rvp
natur
viruslik
envelop
outsid
replicon
insid
permit
quantif
jev
product
entri
replic
timeofaddit
experi
perform
investig
whether
hit
drug
block
entri
step
replic
step
shown
fig
suppress
luciferas
activ
hit
drug
observ
use
treatment
infect
infect
virucid
suggest
drug
inhibit
jev
infect
either
inactiv
viru
directli
block
jev
entri
howev
drug
exert
fulli
inhibitori
effect
ad
h
postinfect
suggest
viral
replic
stage
drug
show
inhibitori
activ
confirm
suggest
investig
inhibitori
effect
drug
jev
replicon
highest
concentr
manidipin
nelfinavir
mesyl
test
babi
hamster
kidney
cell
adjust
respect
shown
five
drug
inhibit
jev
rna
synthesi
dosedepend
manner
neither
drug
inhibit
initi
translat
replicon
rna
fig
confirm
drug
inhibit
jev
infect
stage
replic
hit
drug
exhibit
broadspectrum
antiflaviviru
activ
order
determin
whether
antivir
activ
five
hit
drug
extend
flavivirus
explor
antivir
effect
zikv
similar
find
jev
zikv
titer
decreas
multipl
log
unit
zikv
treat
high
concentr
drug
fig
moreov
zikv
exhibit
higher
sensit
two
calcium
channel
inhibitor
manidipin
cilnidipin
jev
plaqu
format
observ
consist
result
sharp
decreas
level
replic
zikv
rna
level
express
viral
protein
also
detect
fig
notabl
treatment
manidipin
produc
inhibit
viral
replic
translat
viral
yield
taken
togeth
result
indic
hit
drug
could
effect
inhibit
zikv
infect
sinc
drug
exhibit
antijev
effect
stage
viral
replic
test
effect
wnv
use
wnv
replicon
similar
result
jev
dosedepend
reduct
level
wnv
replic
observ
drug
treatment
phenotyp
observ
drug
except
nelfinavir
mesyl
show
effect
concentr
test
fig
c
togeth
result
indic
five
hit
drug
excel
candid
broadspectrum
antiflaviviru
treatment
antivir
effect
calcium
inhibitor
sinc
three
hit
drug
manidipin
cilnidipin
benidipin
hydrochlorid
dhp
vgcc
inhibitor
ask
whether
calcium
antagonist
could
block
jev
infect
address
question
employ
four
differ
class
inhibitor
verapamil
prototyp
phenylalkylamin
paa
vgcc
inhibitor
exhibit
dosedepend
inhibit
jev
african
green
monkey
kidney
vero
human
hepatocellular
carcinoma
cell
fig
consist
inhibitori
effect
dhp
inhibitor
suggest
calcium
channel
play
import
role
jev
infect
cyclosporin
borat
inhibit
efflux
ca
mitochondri
endoplasm
reticulum
er
pool
respect
also
found
block
jev
infect
effect
similarli
treatment
cellperm
ca
chelat
oaminophenoxi
ethanen
n
n
ntetraacet
acid
tetraacetoxymethyl
ester
baptaam
could
also
suppress
jev
infect
taken
togeth
conclud
intracellular
ca
essenti
jev
infect
cytoplasm
calcium
potent
target
antiflaviviru
treatment
select
character
manidipineresist
jev
identifi
viral
target
calcium
channel
inhibitor
select
manidipineresist
viru
serial
passag
jev
presenc
manidipin
virus
passag
show
robust
resist
compar
wild
type
wt
fig
jev
treat
manidipin
viral
titer
higher
wt
respect
individu
viru
clone
isol
two
isol
randomli
select
amplifi
amino
acid
substitut
observ
two
isol
clone
result
glutamin
q
toarginin
r
switch
amino
acid
posit
transmembran
domain
ie
posit
translat
polyprotein
jev
infecti
cdna
clone
fig
sequenc
align
indic
conserv
flavivirus
except
yfv
possess
lysin
posit
fig
conserv
may
account
sensit
jev
zikv
wnv
manidipin
describ
fig
yfv
show
resist
drug
data
shown
confirm
mutat
confer
manidipin
resist
investig
role
function
produc
jev
clone
mutat
introduc
desir
mutat
infecti
cdna
clone
rescu
mutant
virus
investig
biolog
properti
mutant
virus
first
examin
growth
kinet
rescu
virus
shown
fig
mutant
virus
accumul
infecti
virion
reach
highest
titer
h
postinfect
infect
mutant
virus
result
growth
curv
similar
growth
curv
wt
fig
mutant
produc
smaller
amount
virus
h
analysi
plaqu
morpholog
reveal
plaqu
mutant
similar
plaqu
wt
wherea
plaqu
mutant
smaller
wt
next
investig
sensit
four
mutant
virus
manidipin
shown
fig
mutant
virus
resist
manidipin
concentr
manidipin
effici
inhibit
wt
jev
infect
reduc
viral
yield
approxim
log
unit
mutant
virus
resist
manidipin
viral
titer
decreas
less
log
unit
mutant
viru
demonstr
moder
resist
slightli
higher
taken
togeth
could
conclud
critic
confer
manidipin
sensit
also
import
jev
replic
replac
glutamin
basic
amino
acid
confer
resist
manidipin
without
appar
loss
growth
vivo
efficaci
manidipin
manidipin
exhibit
strongest
inhibitori
activ
jev
replic
well
zikv
infect
activ
compar
five
hit
drug
fig
examin
protect
effect
manidipin
jevinduc
lethal
mous
model
anticip
mice
jevinfect
vehicletr
group
start
show
symptom
includ
limb
paralysi
restrict
movement
piloerect
bodi
stiffen
wholebodi
tremor
day
postinfect
within
day
postinfect
mice
jevinfect
group
succumb
infect
mortal
rate
anim
surviv
manidipin
treatment
follow
jev
infect
reduc
mortal
rate
anim
surviv
fig
mice
treat
manidipin
alon
treat
manidipin
infect
jev
show
littl
abnorm
behavior
similar
find
mice
vehicletr
group
result
suggest
manidipin
provid
effect
protect
jevinduc
mortal
relat
protect
effect
viral
load
histopatholog
chang
mous
brain
viral
titer
determin
mous
brain
section
collect
assay
day
day
postinfect
sinc
mice
start
show
symptom
jev
infect
day
postinfect
surviv
mice
recov
day
result
indic
progress
diseas
manidipin
treatment
significantli
reduc
viral
load
infect
mice
compar
infect
mice
receiv
treatment
plaqu
form
either
manidipineor
vehicletr
group
viral
load
undetect
group
day
postinfect
fig
jev
rapidli
clear
blood
inocul
present
lymphat
system
preclin
phase
effect
manidipin
infect
serum
spleen
evalu
earlier
time
point
detect
whether
drug
reduc
peripher
viral
load
shown
fig
manidipin
littl
effect
peripher
jev
infect
indic
manidipin
protect
mice
jevinduc
lethal
decreas
viral
load
brain
similarli
appar
damag
brain
includ
mening
perivascular
cuf
vacuolar
degener
glial
nodul
observ
jevinfect
vehicletr
group
day
postinfect
manidipin
treatment
remark
allevi
phenomena
fig
result
indic
allevi
histopatholog
chang
accompani
reduct
viral
load
well
reduct
rate
mortal
confirm
cur
effect
manidipin
viral
enceph
among
five
hit
drug
manidipin
cilnidipin
benidipin
hydrochlorid
vgcc
inhibitor
well
document
literatur
ca
inhibitor
serv
inhibit
viru
infect
stage
either
entri
replic
even
stage
bud
end
first
review
calcium
inhibitor
includ
current
librari
fdaapprov
drug
found
addit
four
dhp
vgcc
inhibitor
list
fig
two
calcium
inhibitor
ie
flunarizin
dihydrochlorid
lomerizin
hydrochlorid
also
identifi
primari
candid
level
inhibit
similarli
three
calcium
channel
antagonist
nisoldipin
felodipin
nicardipin
hydrochlorid
show
level
inhibit
respect
primari
screen
togeth
calcium
inhibitor
librari
account
nearli
half
calcium
inhibitor
exhibit
level
flaviviru
inhibit
greater
suggest
calcium
especi
calcium
channel
potenti
antivir
target
address
anoth
type
vgcc
inhibitor
verapamil
fdaapprov
drug
yet
includ
drug
librari
use
studi
investig
likewis
ca
chelat
baptaam
well
ca
inhibitor
cyclosporin
target
er
mitochondri
ca
channel
respect
employ
investig
respons
jev
infect
decreas
intracellular
ca
level
line
activ
three
hit
dhp
vgcc
inhibitor
drug
addit
ca
inhibitor
exert
antijev
activ
indic
ca
indispens
jev
infect
thu
ca
inhibitor
might
util
effect
treatment
flaviviru
infect
hit
drug
exert
full
inhibitori
activ
ad
posttreat
believ
ca
import
flaviviru
genom
replic
furthermor
select
genet
analysi
drugresist
virus
reveal
viral
target
manidipin
part
viral
replic
complex
suppos
anchor
viral
replicas
er
membran
meanwhil
ntermin
domain
denv
indic
respons
inhibit
immun
respons
notabl
sever
structur
distinct
compound
identifi
inhibit
flaviviru
replic
intens
target
tmd
thu
conceiv
inhibitor
target
tmd
would
perturb
function
lead
suppress
viral
rna
replic
studi
replac
basic
amino
acid
confer
resist
effect
without
suppress
jev
replic
suggest
posit
could
toler
basic
amino
acid
basic
amino
acid
might
involv
interplay
host
protein
rather
viral
protein
moreov
efficaci
toxic
manidipin
monitor
vivo
manidipin
demonstr
effect
antivir
activ
favor
biocompat
howev
dose
use
studi
higher
dose
typic
use
clinic
repres
one
scenario
commonli
encount
drug
repurpos
manidipin
approv
use
longterm
treatment
hypertens
pulsedos
treatment
manidipin
shorter
period
time
requir
treatment
viru
infect
might
rel
safe
moreov
use
combin
manidipin
ca
inhibitor
might
improv
therapeut
efficaci
reduc
toxic
reduc
risk
resist
develop
besid
three
vgcc
inhibitor
two
hit
drug
pimecrolimu
nelfinavir
mesyl
show
equival
inhibitori
activ
replic
jev
zikv
wnv
although
report
use
pimecrolimu
treatment
infecti
diseas
show
robust
effect
jev
si
maximum
plasma
concentr
c
max
nelfinavir
mesyl
achiev
adult
dose
gml
compar
ic
report
notabl
nelfinavir
mesyl
confirm
inhibit
herp
simplex
viru
replic
sever
herpesvirus
interf
directli
indirectli
later
step
viru
format
glycoprotein
matur
virion
releas
function
herpesvirus
proteas
whether
nelfinavir
mesyl
inhibit
flaviviru
interfer
viru
proteas
offtarget
effect
unknown
understand
mechan
antiflaviviru
effect
drug
might
uncov
novel
target
drug
provid
insight
pathogenesi
flavivirus
find
report
provid
novel
insight
molecular
mechan
underli
flaviviru
infect
offer
new
promis
therapeut
possibl
combat
infect
caus
flavivirus
cell
virus
human
neuroblastoma
vero
cell
cultur
dulbecco
modifi
eagl
medium
hyclon
logan
ut
usa
supplement
fetal
bovin
serum
gibco
grand
island
ny
usa
jev
strain
wnv
replicon
replicon
express
renilla
luciferas
rluc
kindli
provid
bo
zhang
wuhan
institut
virolog
chines
academi
scienc
ca
china
jev
replicon
recombin
viral
particl
rvp
gener
previous
describ
zikv
strain
kindli
provid
european
viru
archiv
goe
global
propag
titrat
vero
cell
optim
ht
assay
condit
cell
densiti
rvp
dose
optim
ht
assay
vero
cell
differ
densiti
cell
per
well
infect
l
rvp
copi
per
well
appropri
cell
densiti
well
rvp
dose
select
compar
sb
ratio
cv
z
valu
differ
condit
previous
describ
dimethyl
sulfoxid
dmso
use
posit
neg
control
respect
ht
assay
fdaapprov
compound
librari
librari
fdaapprov
drug
purchas
selleck
chemic
houston
tx
usa
compound
store
mm
stock
solut
dmso
use
first
round
ht
assay
carri
shown
fig
criteria
use
identifi
primari
candid
appar
cytotox
averag
level
inhibit
duplic
well
criteria
dosedepend
inhibit
cell
viabil
appli
reconfirm
screen
furthermor
cc
compound
calcul
compound
display
si
consid
hit
studi
identif
antivir
effect
five
hit
drug
antivir
effect
drug
evalu
quantit
revers
transcriptionpcr
qrtpcr
immunofluoresc
assay
ifa
plaqu
assay
previous
report
experiment
timelin
depict
fig
ensur
effect
hit
drug
flaviviru
replic
cell
transfect
jev
wnv
replicon
incub
drug
concentr
indic
luciferas
activ
determin
h
h
h
later
respect
timeofaddit
experi
evalu
stage
jev
life
cycl
inhibit
hit
timeofaddit
experi
perform
previous
describ
vero
cell
infect
l
rvp
h
h
test
compound
incub
cell
h
infect
h
infect
h
h
postinfect
h
fig
exclud
possibl
direct
inactiv
effect
drug
rvp
incub
drug
h
mixtur
dilut
infect
vero
cell
twentyfour
hour
later
luciferas
activ
determin
describ
fig
manidipineresist
viru
manidipineresist
viru
gener
passag
jev
vero
cell
presenc
manidipin
passag
use
manidipin
passag
use
manidipin
control
wt
viru
passag
presenc
dmso
parallel
passag
termin
passag
improv
resist
detect
two
manidipineresist
viru
isol
plaqu
purifi
amplifi
presenc
manidipin
viral
rna
extract
amplifi
purifi
sequenc
infecti
cdna
clone
jev
strain
pmwjeat
kindli
provid
wakita
tokyo
metropolitan
institut
neurosci
use
recov
wt
mutant
virus
describ
previous
viru
titer
manidipin
sensit
determin
plaqu
assay
vero
cell
manidipin
administr
jevinfect
mice
adult
femal
balbc
mice
age
week
kept
laboratori
anim
center
wuhan
institut
virolog
ca
wuhan
china
mice
randomli
divid
four
group
mice
per
group
jevinfect
vehicl
tween
plu
dmso
phosphatebuff
salin
pb
treat
group
manidipinetr
group
jevinfect
manidipinetr
group
vehicletr
group
infect
mice
infect
intraperiton
pfu
jev
strain
manidipin
vehicl
treatment
mice
inject
intraperiton
mgkg
bodi
weight
manidipin
pb
tween
dmso
respect
treatment
administ
twice
day
first
day
consecut
administ
day
day
five
mice
group
sacrif
day
postinfect
serum
spleen
tissu
brain
tissu
sampl
collect
viral
titer
determin
histopatholog
investig
fifteen
mice
monitor
daili
morbid
mortal
mice
show
neurolog
sign
diseas
euthan
accord
regul
administr
affair
concern
experiment
anim
china
protocol
review
approv
laboratori
anim
care
use
committe
wuhan
institut
virolog
ca
wuhan
china
